<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02183025</url>
  </required_header>
  <id_info>
    <org_study_id>107.191</org_study_id>
    <nct_id>NCT02183025</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Meloxicam Versus Mefenamic Acid in Patients With Dysmenorrhea</brief_title>
  <official_title>Double Blind Study to Evaluate Efficacy and Safety of Meloxicam 7.5 mg and 15 mg Versus Mefenamic Acid 1500 mg in the Treatment of Dysmenorrhea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To access the efficacy and safety of Meloxicam 7.5 mg and 15 mg once daily compared with&#xD;
      Mefenamic acid 500 mg t.i.d. over a treatment period of 3-5 days, during an observation&#xD;
      period of 3 menstrual cycles, for the symptomatic relief of primary dysmenorrhea&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 1998</start_date>
  <primary_completion_date type="Actual">April 1999</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of severity of lumbar and/or abdominal pain on a visual analogue scale (VAS)</measure>
    <time_frame>Baseline and day 3-5 of each treatment cycle</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Final global assessment of efficacy by patient on a 4-point scale</measure>
    <time_frame>day 3-5 of the second treatment cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final global assessment of efficacy by investigator on a 4-point scale</measure>
    <time_frame>day 3-5 of the second treatment cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final global assessment of tolerability by patient on a 4-point scale</measure>
    <time_frame>day 3-5 of the second treatment cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final global assessment of tolerability by investigator on a 4-point scale</measure>
    <time_frame>day 3-5 of the second treatment cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AE)</measure>
    <time_frame>Up to 4 weeks after last treatment cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of significant laboratory events</measure>
    <time_frame>Up to 4 weeks after last treatment cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of perforations, ulcerations and/or bleedings (PUB) of the upper gastro-intestinal tract</measure>
    <time_frame>Up to 4 weeks after last treatment cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of gastro-intestinal adverse events (GI-AEs)</measure>
    <time_frame>Up to 4 weeks after last treatment cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization stay due to GI-AEs</measure>
    <time_frame>Up to 4 weeks after last treatment cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of additional visits at physician due to GI-AEs</measure>
    <time_frame>Up to 4 weeks after last treatment cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization due to drug related AEs</measure>
    <time_frame>Up to 4 weeks after last treatment cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of withdrawals due to AEs</measure>
    <time_frame>Up to 4 weeks after last treatment cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of AEs on a 3-point scale</measure>
    <time_frame>Up to 4 weeks after last treatment cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of labor and/or daily life disability associated with dysmenorrhea on a VAS</measure>
    <time_frame>Baseline and day 3-5 of each treatment cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in severity of symptomatology associated with dysmenorrhea</measure>
    <time_frame>Baseline and day 3-5 of each treatment cycle</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">337</enrollment>
  <condition>Dysmenorrhea</condition>
  <arm_group>
    <arm_group_label>Meloxicam 7.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Meloxicam 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mefenamic acid 1500 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500 mg three times daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam 7.5 mg</intervention_name>
    <arm_group_label>Meloxicam 7.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam 15 mg</intervention_name>
    <arm_group_label>Meloxicam 15 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mefenamic acid 500 mg</intervention_name>
    <arm_group_label>Mefenamic acid 1500 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching 7.5 mg meloxicam</intervention_name>
    <arm_group_label>Mefenamic acid 1500 mg</arm_group_label>
    <arm_group_label>Meloxicam 15 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching 15 mg meloxicam</intervention_name>
    <arm_group_label>Mefenamic acid 1500 mg</arm_group_label>
    <arm_group_label>Meloxicam 7.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching 500 mg mefenamic acid</intervention_name>
    <arm_group_label>Meloxicam 15 mg</arm_group_label>
    <arm_group_label>Meloxicam 7.5 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female patients between 18 to 40 years&#xD;
&#xD;
          -  Patients experiencing primary (functional) dysmenorrhea during the last 3 consecutive&#xD;
             menstrual periods. Diagnosis will be based on symptoms and clinical signs:&#xD;
             abdominopelvic pain, may radiate to the back and along the thighs; systemic symptoms&#xD;
             including nausea, vomit, diarrhoea, headache, fatigue, nervousness, dizziness; the&#xD;
             symptomatology should be usually some hours to one day before commencement of visible&#xD;
             vaginal bleeding&#xD;
&#xD;
          -  Evaluation of lumbar and/or abdominopelvic pain due to dysmenorrhea &gt; 35 mm through a&#xD;
             100 mm visual analogue scale (VAS)&#xD;
&#xD;
          -  Outpatients&#xD;
&#xD;
          -  Patients granting their written informed consent&#xD;
&#xD;
          -  Therapy with a NSAID (nonsteroidal antiinflammatory drug) is required or recommended&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected hypersensitivity to trial drugs or their excipients, analgesics,&#xD;
             antipyretics or NASIDs&#xD;
&#xD;
          -  Analgesic concomitant treatment (between each cycle paracetamol administration will be&#xD;
             allowed)&#xD;
&#xD;
          -  To initiate hormonal contraception or intrauterine devices after inclusion to this&#xD;
             trial or during the last 3 months&#xD;
&#xD;
          -  Abdominal surgery or pelvic procedure scheduled during the study&#xD;
&#xD;
          -  Patients with organic dysmenorrhea (endometriosis, salpingitis, adnexitis, uterine&#xD;
             retroversion, tubal cysts, ovarian cysts, pathological vaginal secretion, painful&#xD;
             pelvic exploration, etc.)&#xD;
&#xD;
          -  Patients with neoplastic disorders&#xD;
&#xD;
          -  History of recent abdominal or pelvic trauma requiring surgery&#xD;
&#xD;
          -  Peptic ulcer within the past 6 months&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Asthma, nasal polyps, angioneurotic edema or rash following aspirin or NSAIDs&#xD;
             administration&#xD;
&#xD;
          -  Concomitant treatment with anti-coagulants, including heparin and aspirin, lithium or&#xD;
             methotrexate&#xD;
&#xD;
          -  Concomitant administration of other NSAIDs (including aspirin &gt; 150 mg daily) or&#xD;
             analgesics&#xD;
&#xD;
          -  Confinement to bed rest&#xD;
&#xD;
          -  Administration of any NSAID during two days (three for oxicams) before the first&#xD;
             administration of the trial drug&#xD;
&#xD;
          -  Present treatment or treatment within the last two months with corticosteroids&#xD;
&#xD;
          -  Impaired renal function (serum urea &gt; 125 % of the upper limit of normal range; serum&#xD;
             creatinine &gt; 150 % of the upper limit of normal range)&#xD;
&#xD;
          -  Sever liver injury (alanine amino transferase ALAT &gt; 2 x the upper normal range limit&#xD;
             or aspartate amino transferase ASAT &gt; 2 x the upper normal range limit)&#xD;
&#xD;
          -  Hematological disorder (platelet count &lt; 100,000/mm**3, leucocyte count &lt; 3,000/mm**3)&#xD;
&#xD;
          -  Participation in another clinical trial during this study or the previous month&#xD;
&#xD;
          -  Previous participation in this trial&#xD;
&#xD;
          -  Patient unable to comply with protocol&#xD;
&#xD;
          -  Bleeding disorders&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/107/107.191_U01-3305.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 4, 2014</study_first_submitted>
  <study_first_submitted_qc>July 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>August 29, 2018</last_update_submitted>
  <last_update_submitted_qc>August 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysmenorrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meloxicam</mesh_term>
    <mesh_term>Mefenamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

